
Loading, please wait...

Loading, please wait...

Recent research highlights the necessity of rhythm control in FAMR (atrial functional mitral regurgitation) for patients with heart failure with preserved ejection fraction (HFpEF). While mitral regurgitation often accompanies heart failure, atrial fibrillation (AF) significantly complicates the clinical trajectory. Researchers analyzed 218 patients to see how AF affects regurgitation severity and outcomes. Their findings underscore a vital shift in how clinicians should manage these comorbid conditions.
The study revealed a stark contrast between patients in sinus rhythm and those with AF. Specifically, moderate FAMR occurred in 53.3% of AF patients but only 24.5% of those in sinus rhythm. Furthermore, severe FAMR was nearly twice as common in the AF group. Consequently, atrial fibrillation seems to drive significant valve dysfunction within the HFpEF population by promoting atrial remodeling and annular dilation.
Clinical outcomes significantly worsened for AF patients with severe FAMR. These individuals faced a 4.1-fold higher risk of heart failure hospitalization. Moreover, the risk for the composite endpoint, including cardiovascular death, rose by 2.6 times. In contrast, regurgitation severity did not significantly predict outcomes for patients maintaining a normal sinus rhythm. These data suggest that the combination of AF and FAMR creates a high-risk phenotype that requires targeted intervention.
Clinicians should therefore prioritize rhythm control in FAMR as a core pathogenetic strategy. Restoring sinus rhythm may halt left atrial remodeling and reverse annular dilation. This approach could significantly lower the heavy burden of hospitalizations observed in this patient category. Overall, managing the underlying arrhythmia is just as important as treating the heart failure symptoms themselves to improve long-term survival.
FAMR is a type of heart valve dysfunction where the mitral valve leaks due to atrial enlargement and annular dilation. It typically occurs in patients with atrial fibrillation despite having a preserved left ventricular ejection fraction.
Maintaining sinus rhythm helps reduce the severity of mitral regurgitation. Research shows it specifically lowers the risk of heart failure rehospitalization, which is significantly elevated when AF and severe regurgitation coexist.
Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional healthcare. Always consult a qualified physician for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Study confirms that rhythm control in FAMR is essential for HFpEF patients, as AF-linked severe regurgitation 4.1x increases heart failure hospitalization....
8 months ago

As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today